Novaccess Global Inc. · OTC:XSNX
Novaccess Global — Shareholder Meeting (November 2022)
31 slides from Novaccess Global's shareholder meeting presentation, Nov 23, 2022
Slide 1: NovAccess
NovAccess
Slide 2: Annual Shareholders' Meeting
5 { _ > & he NovAcces Global Annual Shareholders’ Meeting Dr. Dwain Irvin, CEO Neil Laird, CFO John Cassarini, Chairman of the Board November 21st, 2022
Slide 3: Forward-Looking Statements
Forward-Looking Statements This information package contains forward-looking statements, which includes forecasts and timelines. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “will”, “proposes”, “expects”, “estimates”, “intends”, “anticipate
Slide 4: Overview
Overview XSNX Introductions XSNX Technology/Asset Overview Financial Update, CFO Official Portion/Voting r | Market Analysis/ Investor Highlights NovAccess
Slide 5: Pre-IND stage biopharmaceutical company developing next-generation immunotherapies
| Pre-IND stage biopharmaceutical company developing next-generation immunotherapies to treat brain cancer | An SEC-registered, OTCQB Markets, public company seeking FDA approval for a human clinical trial | An expert scientific and managerial team focused on bringing novel cancer therapeutics to ma
Slide 6: Our Focused Mission
Our Focused Mission Acquisition of cutting-edge technologies in the life sciences . Enhance and accelerate bringing to market novel brain tumor immunotherapies Utilization of our expert ne advisory board to accelerate going to market Rosca | Aecele spit ita |
Slide 7: Each Contributor, an Expert in their Field
Each Contributor, an Expert in their Field - Highly Focused, yet Adaptable Scientific Advisory Board NovAccess ba
Slide 8: Technology/Asset
Technology/Asset
Slide 9: Immunotherapy for Glioblastoma
Immunotherapy for Glioblastoma More than 21,000 brain tumors diagnoses were estimated for 2021 in the U.S. + Glioblastoma is the most common primary adult brain tumor (e.g. Ted Kennedy, John McCain) + Five-year survival rates are less than 5% for Glioblastoma + Despite 40 yr. advances Chemotherapy a
Slide 10: Glioblastoma - Patient Advocate Interview
Glioblastoma - Patient Advocate Interview
Slide 11: TLR-AD1 Immunotherapy for Glioblastoma
TLRAD! Immunotherapy for Glioblastoma Standard of Care: Surgical resection followed by radiation and chemotherapy + 15-month median survival No Cures, additional Glioblastoma therapies needed Immunotherapy: 3 Major Types 1. Administration of antigen-pulsed dendritic cell (DC) immunotherapy 2. Checkp
Slide 12: TLR-AD1 Immunotherapy for Glioblastoma
a TLRAD! Immunotherapy for Glioblastoma ine (Ist Generation) + Improves survival in responders (Phase | and II) + Not a cure - Reduces chance of Glioblastoma recurrence + Needs improvement-survival rates, outcomes NovAccess | Aecelentin Themph Yonanitimn | WRG XSNX =
Slide 13: TLR-AD1 Immunotherapy for Glioblastoma
TLRAD! Immunotherapy for Glioblastoma munotherapy: TLR-AD1 + 3rd Generation + 35% improvement over Ist generation in animals * Ist and 2nd Generation > Improves survival in Glioblastoma responders (Phase |, II) * NOT a cure - Reduces chance of Glioblastoma recurrence Neca | Predict | HHREL. XSNX ict
Slide 14: TLR-AD1 Immunotherapy for Glioblastoma
STLRAD! Immunotherapy for Glioblastoma kk °°” Neurosurgeon isolates Tumor and Immune Cells - Sends to Lab TUMOR ANTIGEN CELLS: BLOOD ANTIGEN- PRESENTING. NovAccess | Aecelentin Themph Yonanitin | WRGL XSNX =
Slide 15: TLR-AD1 Immunotherapy for Glioblastoma
TLRAD! Immunotherapy for Glioblastoma —k—> Immune Cells Process Tumor Antigens Utilizing TLR-AD1 Technology BULK TUMOR LYSATE ANTIGEN-PRESENTING. CELLS (Dendritic Immune Cells) | NovAccess | els. Fata Pee | WHKET- XSNX
Slide 16: TLR-AD1 Immunotherapy for Glioblastoma
TLR AD! immunotherapy for Glioblastoma TLR-AD! Glioblastoma Vaccine Administered Glioma Tumor Cell Lysate Antigen specific or antigens derived from bulk lysate combined with Toll- like receptor (TLR) adjuvants ‘Intelligence-Briefed’ Immune
Slide 17: TLR-AD1 Summary
TLRAD! summary * Parent immunotherapy shows improvement in patient survival over standard of care (chemotherapy and radiation) in Phase | and Il Human Clinical trials. + TLR-AD] out-performs parent immunotherapies in pre-clinical animal trials. * FDA reviews TLR-AD1 data during pre-IND interaction a
Slide 18: Market Analysis
Market Analysis
Slide 19: Immunotherapy for Glioblastoma
Immunotherapy for Glioblastoma 2018, Global, $700 Million Market size, CAGR 9.3% (GlobalData Inc. 2019) 2026, US, 2.9 Billion Market Size (GlobalData Inc. 2019) Unmet need - No current immunotherapy for brain tumors We expect significant market penetration after registration
Slide 20: Investor Highlights
Investor Highlights Glioblastoma first indication targeted: Large, unmet need + Market valued over $2.9 Billion annually, after 2026 Brain cancers today has no immunotherapy treatment, leaving only the option of highly invasive surgery, toxic chemotherapy, and radiation treatments
Slide 21: Investor Highlights (Future Assets)
Investor Highlights (Fu re Ass@ts) Novel therapeutics, diagnostics and medical devices to improve the quality of life for: + Glioblastoma patients and others # Predictive technologies to help us achieve these goals + Later stage technology, close to market-ready or in the market + Additional assets
Slide 22: Financial Update
Financial Update Neil Laird, CFO
Slide 23: Financial Update
Financial Update Four Areas of Focus + Raising Capital - Funding + Improving our Capital Structure + Management of Expenses + Ensuring Compliance with our Reporting Requirements
Slide 24: Funding and Expense Management
Funding and Expense Management * We have maintained good control over expenses and managed them to the minimum required to move our platform technology forward. * Cash used in operations for the nine months ended September 30, 2022, was $706,954 and was mainly spent on payroll, consulting fees in re
Slide 25: Capital Structure
Capital Structure + March 2022, purchased and redeemed 24,400 Series B preferred stock + — Significantly reduced the overhang from these shares that had a 1:10,000 conversion ratio into common stock + August 2022, upgraded our listing to OTCQB + Facilitated our ability to file an S-1 + September 202
Slide 26: Compliance
Compliance + AIl SEC filings have been filed on time since the 10-Q for the period ending March 31, 2021. The 10-K filing for the year ended September 30, 2022, is in process and currently on schedule. NovAccess ba
Slide 27: Outstanding Shares as of 9/30
tstanding Shares as of 9/3 Percentage All Others 7,399,547 Dwain Irvin, CEO 1,800,000 9.7% AJB Capital (based on 13G) 1,574,543 8.5% Neil Laird, CFO 260,000 1.4% Innovest Global 7,500,000 18,534,090
Slide 28: 2022 Technology Milestones Achieved
2022 Technology Milestones Achieved + Q42022 - FDA provides Orphan Drug Designation for TLR-AD1 * Q32022 - Completed negotiations with world class drug manufacturer to produce TRL-AD1 for human trials
Slide 29: 2023 Goals to Increase XSNX Value
2023 Goals to Increase XSNX Value + Obtain bridge financing + Complete Data generation for IND application + File IND application with the FDA to obtain approval to begin Human Clinic Trials + — Uplist to Nasdaq + Obtain presumed FDA approval to Start Human Clinical Trials + Considering additional a
Slide 30: Official Portion
Official Portion Voting on Proposals 30
Slide 31: Thank You!
Noy Access Global Thank You! For questions and comments about the meeting, please contact: info@novaccessglobal.com Phecelerndiin: Tarra he Innesinftin: novaccessglobal.com
NovAccess Global — Shareholder Meeting (November 2022) on 6ix